2,250 results on '"Multiple myeloma -- Care and treatment"'
Search Results
2. CARsgen's first enrolled subject in the THANK-u Plus platform-based allogeneic CAR-T trial achieves sCR at week 4
3. Dr Reddy's inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe
4. China NMPA approves Sanofi's Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant
5. EMA committee approves Sanofi's anti-CD38 therapy, Sarclisa in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
6. Immuneel Therapeutics Launches Affordable CAR T-Cell Therapy for Blood Cancer in India
7. Immuneel Therapeutics launches Qartemi, India's first global CAR T-cell therapy for non-Hodgkin's lymphoma
8. Studies from Institute of Hematology and Blood Diseases Hospital Have Provided New Information about Hemophagocytic Lymphohistiocytosis (Uncommon Biphasic Car-t Expansion Induces Hemophagocytic Lymphohistiocytosis-like Syndrome and Fatal ...)
9. Research and Development Researchers Target Multiple Myeloma (Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities)
10. EMA human medicine committee recommends approval of Sanofi's Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma
11. New Findings from Sichuan University in the Area of Multiple Myeloma Published (Evaluating myocardial involvement in patients with multiple myeloma at different stages a cardiac MR T1 mapping study)
12. GSK announces positive results from head-to-head DREAMM-7 phase III trial of Blenrep in combo with bortezomib plus dexamethasone to treat r/r multiple myeloma
13. Aurigene Reports Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
14. Janssen-Cilag's Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible
15. Antengene's Xpovio in combo with bortezomib & dexamethasone gets South Korean regulatory approval to treat adult patients with multiple myeloma
16. Researchers at Monterrey Institute of Technology and Higher Education Publish New Data on Cell Therapy (State of the Art on CAR T-Cell Therapies for Onco-Haematological Disorders and Other Conditions)
17. New Combination-Based Approaches to NDMM: What Do the Data, the Experts, and Patients Say?
18. MULTIDISCIPLINARY CARE
19. Johnson & Johnson announces updated results from phase 1b RedirecTT-1 study of Talvey & Tecvayli in patients with RRMM including those with extramedullary disease
20. Poseida Therapeutics reports data from Phase 1 trial of P-BCMA-ALLO1
21. Johnson & Johnson provides updated results from Phase 1b TRIMM-2 study
22. BioLineRxlLaunches digital resource for MM patients 'Mobilization Matters'
23. BioLineRxl launches digital resource for MM patients 'Mobilization Matters'
24. GSK announces CDE of NMPA in China granted BTD for Blenrep
25. ALX Oncology doses first patients for UMBRELLA phase 1/2 study with Sanofi to evaluate evorpacept in combination with Sarclisa
26. Lyell Immunopharma announces initial data from phase 1 trials of an ROR1-targeted CAR T cell product candidate, LYL797
27. Johnson & Johnson's Darzalex Faspro approved by FDA in multiple myeloma
28. Johnson & Johnson announces positive results from phase 3 CARTITUDE-4 study of Carvykti to treat relapsed or lenalidomide-refractory multiple myeloma
29. Johnson & Johnson announces results from Phase 3 CARTITUDE-4 study
30. Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
31. Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma
32. IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health
33. Chromatin Bioscience's synthetic promoter supports EsoBiotec's ESO-T01 CAR-T therapy as it enters the clinic
34. Immunologist Carl H. June receives the 'Abarca Prize' for the development of CAR-T therapies for blood cancers
35. Immunologist Carl H. June receives the 'Abarca Prize' for the development of CAR-T therapies for blood cancers
36. Johnson & Johnson surprises with growth in sales of oncology treatments beating Wall Street forecasts
37. AbbVie announces dosing first patient with ABBV-383 in the CERVINO Phase 3 study
38. Poseida: Phase 1 data supports potential of P-BCMA-ALLO1 therapy in MM
39. IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel FUCASO by the Singapore Health Sciences Authority HSA
40. Findings in Multiple Myeloma Reported from University of Patras (Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients)
41. Data on Multiple Myeloma Reported by Researchers at University Hospital of Split (Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?)
42. Sarclisa approved in EU for front-line treatment of transplant-ineligible multiple myeloma
43. Sarclisa approved in EU for front-line treatment of transplant-ineligible multiple myeloma
44. Research from All India Institute of Ayurveda Provide New Insights into Multiple Myeloma (Integration of Ayurveda in the management of multiple myeloma - A case report on therapeutic synergism)
45. Reports Outline Immunoglobulins Study Results from Istanbul University (Precision Medicine in Multiple Myelom)
46. Data from Zhejiang University Advance Knowledge in Hepatitis B Virus (Reactivation of Suspected Hepatitis B Virus In a Patient With Multiple Myeloma Following Chemotherapy: a Case Report)
47. Investigators from Medical College of Wisconsin Zero in on Multiple Myeloma (Racial and Ethnic Disparities In Autologous Hematopoietic Cell Transplantation Utilization In Multiple Myeloma Have Persisted Over Time Even After Referral To a ...)
48. Genes Highlight Who'll Benefit From Multiple Myeloma Therapy
49. Baroness Ritchie of Downpatrick ask His Majesty's Government what steps they plan to take to ensure blood cancer patients are given greater choice in decisions about their treatment and care within the 10-year NHS plan
50. JAMA Oncology Publishes Phase 1b|2 Study Data on IASO Bio's Equecabtagene Autoleucel (Fucasotm) in the Treatment of Relapsed|Refractory Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.